160 Health International Ltd.

As of December 31, 2025, 160 Health International Ltd. carries a market capitalization of 18.50B, placing it among publicly traded companies globally. Its enterprise value stands at 18.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, 160 Health International Ltd. has 336.45M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 23.03, and the price-to-book ratio stands at 69.56.

These figures are as of December 31, 2025. The EV/Sales ratio of 25.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.33B versus a market cap of 18.50B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, 160 Health International Ltd. maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.73, indicating elevated leverage, while an interest coverage ratio of -10.89 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -13.80, reflecting losses generated across the asset base. The company generates approximately 1.49M in revenue per employee across its workforce of 487.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 43.62 indicates how many times 160 Health International Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, 160 Health International Ltd. recorded an income tax benefit of -3.11M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -86.06M and -81.23M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, 160 Health International Ltd.'s stock has declined approximately 94.59% over the past 52 weeks. The 50-day moving average sits at 6.84, while the 200-day moving average is 35.65.

Over the twelve months ended December 31, 2025, 160 Health International Ltd. generated 725.46M in revenue and converted that into -81.23M in net income, yielding earnings per share of -0.27. EBITDA reached -75.62M, while operating income came in at -70.49M.

As of December 31, 2025, 160 Health International Ltd. holds 443.83M in cash and equivalents against 278.07M in total debt, resulting in a net debt position of -175.60M. Total book value stands at 266.01M, with working capital of 232.44M providing operational flexibility.

160 Health International Ltd. produced -127.36M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -4.62M in capital expenditures, free cash flow totaled -131.98M - equivalent to -0.43 per share.

Over the twelve months ended December 31, 2025, 160 Health International Ltd. posted a gross margin of 26.10, reflecting its pricing power and cost economics. The operating margin of -9.72 and net profit margin of -11.20 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -0.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.90, meaning 160 Health International Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, 160 Health International Ltd. has an Altman Z-Score of 17.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.